AZD8055

Catalog No.S1555

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Cited by 113 Publications

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Nat Med, 2017, 23(2):200-212

PubMed: 28067899 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):177-190

PubMed: 27939219 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):255-63

PubMed: 25564516 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):245-54

PubMed: 25564517 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5107-5121

PubMed: 31164374 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Sci Signal, 2019, 12(612)

PubMed: 31848319 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627299 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):366-377

PubMed: 30661989 ( click the link to review the publication )
Am J Cancer Res, 2019, 9(9):1922-1937

PubMed: 31598395 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

Cancer Gene Ther, 2019, 10.1038/s41417-019-0117-7

PubMed: 31257364 ( click the link to review the publication )

Biochem J, 2019, 476(20):3081-3107

PubMed: 31665227 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):21-36

PubMed: 30831322 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):465-478

PubMed: 29593330 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(8):1338-1346

PubMed: 29345254 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2735-2743

PubMed: 29720580 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2207

PubMed: 29263324 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )
Biochim Biophys Acta Mol Cell Res, 2017, 1864(10):1554-1565

PubMed: 28641977 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(5):527-39

PubMed: 27043084 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(1):22-8

PubMed: 26595461 ( click the link to review the publication )

EMBO J, 2016, 35(17):1902-22

PubMed: 27481935 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):538-52

PubMed: 26686971 ( click the link to review the publication )

J Biol Chem, 2016, 291(12):6262-71

PubMed: 26755732 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1515-20

PubMed: 27565731 ( click the link to review the publication )

Int J Endocrinol, 2016, 2016:5286972

PubMed: 27990160 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Autophagy, 2015, 11(2):285-97

PubMed: 25801301 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Sci Signal, 2015, 8(375):ra42

PubMed: 25943352 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )
Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Leukemia, 2014, 28(5):1092-102

PubMed: 24135829 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5756-67

PubMed: 25316808 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):649-56

PubMed: 24297300 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )
Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Hypertens, 2013, 31(2):303-11

PubMed: 23303355 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	M2fZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTudW5KSzVyPUCuNFI{OzFizszN	NYPJSYtRW0GQR1XS
NCI-H720	NUTGOmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkX3TWM2OD1yLkCyPVM5KM7:TR?=	M2r5XnNCVkeHUh?=
KARPAS-45	M3vWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzQPW5KSzVyPUCuNFM{PzFizszN	NFrVb4NUSU6JRWK=
EW-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTBwMESwOVYh\|ryP	NGXtXJlUSU6JRWK=
SBC-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPiVmtWUUN3ME2wMlA1PThzIN88US=>	NVjHbJF1W0GQR1XS
NCI-H209	NWTNR49qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\rWVNKSzVyPUCuNFU1PTNizszN	M3viSnNCVkeHUh?=
EoL-1-cell	M3TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFz3eXJKSzVyPUCuNFY2PjlizszN	NFvkXZJUSU6JRWK=
H9	M3zuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTBwME[2PVIh\|ryP	NXX6bmFOW0GQR1XS
AN3-CA	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFn6PHpKSzVyPUCuNFc6PTFizszN	MW\TRW5ITVJ?
HH	NYjQTZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTBwMEiwNFkh\|ryP	MnzZV2FPT0WU
KU812	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPSW4lKSzVyPUCuNFgxPDNizszN	NITheWVUSU6JRWK=
DU-4475	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV32TppUUUN3ME2wMlA5ODR5IN88US=>	MmDTV2FPT0WU
CTV-1	NFn6fFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jBXGlEPTB;MD6wPFY1OSEQvF2=	Mm\JV2FPT0WU
BV-173	NYrINpJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\RNlNKSzVyPUCuNFkxPjFizszN	MUfTRW5ITVJ?
ES5	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjCZY5nUUN3ME2wMlA6OzVizszN	MWjTRW5ITVJ?
G-402	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIKxeZNKSzVyPUCuNFk6QCEQvF2=	MXrTRW5ITVJ?
MV-4-11	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULxSndLUUN3ME2wMlExOzR5IN88US=>	M{TYfXNCVkeHUh?=
NB69	NGq3bodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTBwMUO1JO69VQ>?	MoPjV2FPT0WU
EGI-1	NWHKb\|hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnZXJpKSzVyPUCuNVM2OzFizszN	MULTRW5ITVJ?
EW-18	NFzxT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvUZnVKUUN3ME2wMlE1ODd\|IN88US=>	M4fZd3NCVkeHUh?=
ME-180	NY\SWYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjk[5F1UUN3ME2wMlE1PjhzIN88US=>	MXzTRW5ITVJ?
D-283MED	M2C1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7mbHRvUUN3ME2wMlE1PzJ\|IN88US=>	M4DZS3NCVkeHUh?=
NB14	M2fKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfxOldKSzVyPUCuNVY1PDdizszN	NYTwTY5kW0GQR1XS
Ramos-2G6-4C10	M3;BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nWV2lEPTB;MD6xOlk5OyEQvF2=	NX:zW5M1W0GQR1XS
NBsusSR	M{Prdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwMUewNVkh\|ryP	NHHKbHRUSU6JRWK=
LAMA-84	NYjwZ\|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfnRpBKSzVyPUCuNVgxOzJizszN	M2DNSXNCVkeHUh?=
NCI-H1581	NYPhelJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTBwMUi5OlYh\|ryP	NXTH[mFEW0GQR1XS
A204	NGH1cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXpTWM2OD1yLkG4PVch\|ryP	MWTTRW5ITVJ?
A549	NXP5flJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;WTWM2OD1yLkG5OVUh\|ryP	M17kSXNCVkeHUh?=
CAL-51	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH31T\|dKSzVyPUCuNVk3PTFizszN	NXuyV3QyW0GQR1XS
NKM-1	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELIPXlKSzVyPUCuNlAxOjlizszN	NIHxR5dUSU6JRWK=
LoVo	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwMkCyNFIh\|ryP	NGnveo1USU6JRWK=
HAL-01	NInyW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED1epVKSzVyPUCuNlAzQTdizszN	NXvVcZlPW0GQR1XS
HCC2218	NX;6OodpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\Jd2lEPTB;MD6yNFY5QCEQvF2=	NFvCXIdUSU6JRWK=
BEN	NWqxW5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDsNo5KSzVyPUCuNlEzQTNizszN	MlLaV2FPT0WU
LC-2-ad	NVr6O2g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTCS5JJUUN3ME2wMlIzODh2IN88US=>	NEW0bYdUSU6JRWK=
LXF-289	M4jYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwMkWwOFEh\|ryP	MkTzV2FPT0WU
HGC-27	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2wTWM2OD1yLkK2OFE1KM7:TR?=	MYDTRW5ITVJ?
LK-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLWdlhiUUN3ME2wMlI3QDJ2IN88US=>	MkLJV2FPT0WU
CTB-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\ocWlEPTB;MD6yO\|IyPSEQvF2=	NYnWdoVTW0GQR1XS
697	M{P2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jBVWlEPTB;MD6yO\|M3PyEQvF2=	Mn3QV2FPT0WU
ES7	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLITWM2OD1yLkK3N\|g{KM7:TR?=	MV\TRW5ITVJ?
MG-63	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnn0TWM2OD1yLkK3OFA4KM7:TR?=	NV\SV4hDW0GQR1XS
T47D	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwMke0O\|Uh\|ryP	NIX6WIVUSU6JRWK=
RPMI-8226	NVjacW42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrlRlVKSzVyPUCuNlg2QDlizszN	MoLLV2FPT0WU
NCI-H292	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTBwMkmxOlQh\|ryP	NYHxRVE6W0GQR1XS
HT	NH7QZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr4UHgxUUN3ME2wMlI6OzhizszN	M4XxXHNCVkeHUh?=
A3-KAW	NHL3TXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMkm3OEDPxE1?	MVXTRW5ITVJ?
LB2241-RCC	M4\rRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DoemlEPTB;MD6zNFE6QCEQvF2=	NGHQU5hUSU6JRWK=
BB65-RCC	M2j2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWP3[pNWUUN3ME2wMlMxQDB3IN88US=>	MnTXV2FPT0WU
G-401	NYnBeWNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXqOXdKSzVyPUCuN\|A6QDZizszN	MUfTRW5ITVJ?
TYK-nu	NGnJNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTwcVVKSzVyPUCuN\|E5PjRizszN	M1nE[XNCVkeHUh?=
NCI-SNU-1	Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml62TWM2OD1yLkOyN\|MyKM7:TR?=	NEexO4pUSU6JRWK=
CHL-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXad5ptUUN3ME2wMlMzPzB\|IN88US=>	M1XKd3NCVkeHUh?=
P30-OHK	NWi3[IxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\6eGlEPTB;MD6zNlcxPSEQvF2=	MlzVV2FPT0WU
PA-1	M4\ORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTBwM{O2NVkh\|ryP	MUnTRW5ITVJ?
LB1047-RCC	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPBVphKSzVyPUCuN\|QxPDdizszN	MlfiV2FPT0WU
EM-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvWTWM2OD1yLkO0NVg5KM7:TR?=	MlnuV2FPT0WU
VA-ES-BJ	NEnpeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jUdGlEPTB;MD6zOFI3QCEQvF2=	MmTjV2FPT0WU
NCI-H520	NXO4PZFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkf0TWM2OD1yLkO0PFM1KM7:TR?=	MojXV2FPT0WU
ECC10	NXLscFA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjW[ng3UUN3ME2wMlM2ODN3IN88US=>	NVrtS4RjW0GQR1XS
LNCaP-Clone-FGC	NX;ycHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknCTWM2OD1yLkO1N\|E1KM7:TR?=	NH\rSolUSU6JRWK=
ES8	MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DYOGlEPTB;MD6zOlU2OyEQvF2=	NIe2VlJUSU6JRWK=
HuO-3N1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjmeZA1UUN3ME2wMlM5Ozd7IN88US=>	M3m5UHNCVkeHUh?=
L-363	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLOSZpFUUN3ME2wMlM6ODJ4IN88US=>	NYG2Nnl6W0GQR1XS
SK-LU-1	NHLFWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTBwM{myNFgh\|ryP	MonWV2FPT0WU
MCF7	NFH2RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PTRWlEPTB;MD60NFU{KM7:TR?=	M{XvZ3NCVkeHUh?=
HuO9	NH65cWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvuNpppUUN3ME2wMlQxPjZ5IN88US=>	MVTTRW5ITVJ?
BHT-101	NEjDeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrs[WZGUUN3ME2wMlQxPzh5IN88US=>	NWK1NXFzW0GQR1XS
MZ2-MEL	M2G4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLjZYY{UUN3ME2wMlQxQDh{IN88US=>	NHLreWhUSU6JRWK=
NOS-1	Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4j4[GlEPTB;MD60NVA4PCEQvF2=	NFPR[o5USU6JRWK=
NEC8	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPZOXpsUUN3ME2wMlQyPjl3IN88US=>	NVjod2tsW0GQR1XS
COR-L88	Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rGR2lEPTB;MD60NlI3PyEQvF2=	MoS4V2FPT0WU
MFM-223	NUfTfY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;NTWM2OD1yLkSyOlE4KM7:TR?=	NVnhTpNGW0GQR1XS
HSC-3	MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrFTWM2OD1yLkSyPVA5KM7:TR?=	NEjCXGRUSU6JRWK=
OVCAR-5	NUfQUWt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnuSWRrUUN3ME2wMlQzQTN\|IN88US=>	NXPD[Wd3W0GQR1XS
MFE-280	NY\pTXd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3qwOmlEPTB;MD60N\|A{OiEQvF2=	M2L4cXNCVkeHUh?=
KP-N-YS	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3PdVZKSzVyPUCuOFMxPyEQvF2=	M3P2fHNCVkeHUh?=
EPLC-272H	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfvRYhPUUN3ME2wMlQ{ODd5IN88US=>	MYrTRW5ITVJ?
KE-37	NWGzbHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTBwNEOyOFch\|ryP	M4riZnNCVkeHUh?=
HuH-7	MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLKTWM2OD1yLkSzN\|czKM7:TR?=	M2LJS3NCVkeHUh?=
CHP-212	M33JSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HqPGlEPTB;MD60N\|Y6PyEQvF2=	MlrXV2FPT0WU
SK-MES-1	M1nwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnG3TWM2OD1yLkSzPFQ5KM7:TR?=	NIf5XYNUSU6JRWK=
SJSA-1	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nvXGlEPTB;MD60OFU2PCEQvF2=	NGT5RmFUSU6JRWK=
QIMR-WIL	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXSdZdKSzVyPUCuOFUyPSEQvF2=	NHjXPHFUSU6JRWK=
ES4	NW\KOJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmn0TWM2OD1yLkS1N\|M3KM7:TR?=	NV7tV5NmW0GQR1XS
TI-73	NYjnWpJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\lTWM2OD1yLkS1Olg3KM7:TR?=	NVzkV\|FGW0GQR1XS
COLO-684	M1PTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvkXGJKSzVyPUCuOFU4OjZizszN	NXTDO3lZW0GQR1XS
GCIY	NXzubVBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLETWM2OD1yLkS1O\|U1KM7:TR?=	MV7TRW5ITVJ?
JVM-3	NWezXG5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTBwNE[yPVIh\|ryP	NHPselBUSU6JRWK=
MPP-89	NVPEPIhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PpUWlEPTB;MD60Olk1PyEQvF2=	MnnmV2FPT0WU
M14	NHXiU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3i2dGlEPTB;MD60O\|E4KM7:TR?=	M2nkSHNCVkeHUh?=
SW962	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwNEexPUDPxE1?	M3HWO3NCVkeHUh?=
VM-CUB-1	NWn5OpE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXN[\|doUUN3ME2wMlQ4Ojh4IN88US=>	NXLlZ2lNW0GQR1XS
A101D	NYPyUGRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DzPWlEPTB;MD60PFk3QCEQvF2=	MXrTRW5ITVJ?
DB	M1jn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1G3ZmlEPTB;MD61NFAzOSEQvF2=	MmD1V2FPT0WU
KNS-62	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzqWHNKSzVyPUCuOVA2PjhizszN	M16yenNCVkeHUh?=
NCI-H460	M1:2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzO[lNKSzVyPUCuOVA2QTdizszN	NE\VVWpUSU6JRWK=
MDA-MB-361	NWLG[oJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LLVGlEPTB;MD61NFg4KM7:TR?=	NH3TN49USU6JRWK=
DOK	Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWixc41sUUN3ME2wMlUyOzN\|IN88US=>	Mlf5V2FPT0WU
CAL-39	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml[4TWM2OD1yLkWyNlY5KM7:TR?=	NFW2epdUSU6JRWK=
HT-1080	NGrOcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPETWM2OD1yLkWyOVQ{KM7:TR?=	M3zafnNCVkeHUh?=
GR-ST	M1zhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\1XpltUUN3ME2wMlU{ODF3IN88US=>	MUnTRW5ITVJ?
J-RT3-T3-5	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHSXVVKSzVyPUCuOVMyQTVizszN	MoWyV2FPT0WU
NCI-H1793	NU\keYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vjcWlEPTB;MD61N\|Q1PyEQvF2=	NVP5T5l7W0GQR1XS
NCI-H1355	M1nCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;EfnVLUUN3ME2wMlU{QDd6IN88US=>	MkLBV2FPT0WU
YH-13	Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorWTWM2OD1yLkW0PVM5KM7:TR?=	MU\TRW5ITVJ?
LOXIMVI	NHHufJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwNUWxNlMh\|ryP	NI[wd4xUSU6JRWK=
ES1	NGO5blVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvXbWZKSzVyPUCuOVU2OThizszN	NYr3XJZoW0GQR1XS
GAMG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljjTWM2OD1yLkW1OlU5KM7:TR?=	NXHMSJl6W0GQR1XS
SK-MEL-28	NGG0PJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwNUW5NUDPxE1?	NX;Sdo8{W0GQR1XS
KG-1	MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTBwNU[4PFQh\|ryP	NIXldGlUSU6JRWK=
HOS	NGfSdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTBwNUexPVIh\|ryP	M4Xod3NCVkeHUh?=
PANC-08-13	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;sVZFzUUN3ME2wMlU4Ozh7IN88US=>	NHjaOVZUSU6JRWK=
SW780	NEL5OWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3qwcGlEPTB;MD61O\|U6PSEQvF2=	NUfFempKW0GQR1XS
MDA-MB-175-VII	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTEWopKSzVyPUCuOVc4PDFizszN	NWLEOZFuW0GQR1XS
MSTO-211H	M{nDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTBwNUe3OVEh\|ryP	MmflV2FPT0WU
ML-2	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTBwNUi0O\|gh\|ryP	MmewV2FPT0WU
SCC-4	M3TqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfZdGVPUUN3ME2wMlU5PTRzIN88US=>	M4fZOXNCVkeHUh?=
NCI-H1048	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3JXVBjUUN3ME2wMlU5PjR3IN88US=>	Ml\vV2FPT0WU
NCI-H28	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4OyfmlEPTB;MD61PFY4PSEQvF2=	MoDZV2FPT0WU
BCPAP	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTBwNUi3PVEh\|ryP	M4fGNXNCVkeHUh?=
PC-14	NGTrNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjRTWM2OD1yLkW4PVch\|ryP	NXX6[oU3W0GQR1XS
OAW-42	MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFj5fJBKSzVyPUCuOVkyPjJizszN	MVnTRW5ITVJ?
IA-LM	M3jjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHn3dY9KSzVyPUCuOVk3ODlizszN	M4[2TnNCVkeHUh?=
Hs-578-T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HyZmlEPTB;MD61PVg2OSEQvF2=	NUDpcXh6W0GQR1XS
H4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXhNWdKSzVyPUCuOlAxQTRizszN	MUnTRW5ITVJ?
HL-60	M4DIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTBd3BEUUN3ME2wMlYxOzVzIN88US=>	NXnqXopXW0GQR1XS
NCI-H1437	M{Lqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTBwNkC2NVkh\|ryP	M3TYV3NCVkeHUh?=
KGN	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLUZoxLUUN3ME2wMlYyODR7IN88US=>	MorzV2FPT0WU
NCI-H2452	M1HNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XLO2lEPTB;MD62NVkyPyEQvF2=	NIL5eIhUSU6JRWK=
BFTC-905	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwNkKxNlYh\|ryP	NWHxVGx6W0GQR1XS
CAMA-1	M3rldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjxcppKSzVyPUCuOlIyPTJizszN	NHvVTm1USU6JRWK=
SK-NEP-1	NX3KcJBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHqd3NKSzVyPUCuOlI2ODJizszN	NEHVSmRUSU6JRWK=
NCI-H522	MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTBwNkK5PVIh\|ryP	NHm5V2xUSU6JRWK=
SW1710	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHTdVNwUUN3ME2wMlY{OTZ5IN88US=>	M1rXfXNCVkeHUh?=
RVH-421	NUTWfmplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoniTWM2OD1yLk[zOlM6KM7:TR?=	M1zSU3NCVkeHUh?=
SK-MEL-2	NGH3O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LSfmlEPTB;MD62OFE2OyEQvF2=	NYXrPZZMW0GQR1XS
KYSE-150	M4DReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHXXWJKSzVyPUCuOlYyQDZizszN	M1fycHNCVkeHUh?=
MOLT-13	M2DIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vD[GlEPTB;MD62OlU{PyEQvF2=	MkjIV2FPT0WU
SK-OV-3	NX\QTYNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TGRWlEPTB;MD62O\|E5PyEQvF2=	MWDTRW5ITVJ?
IGROV-1	MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVq1NHlkUUN3ME2wMlY4PDVizszN	M3XpWXNCVkeHUh?=
MOLT-4	NV;aTm86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFf1cHJKSzVyPUCuOlc3QDlizszN	M4DVTXNCVkeHUh?=
MEL-HO	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwNke3OVIh\|ryP	MlzRV2FPT0WU
MDA-MB-157	NHLWdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Lm[WlEPTB;MD62O\|gyKM7:TR?=	M3u2c3NCVkeHUh?=
MN-60	M3HUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXRbFA4UUN3ME2wMlY4QDR4IN88US=>	Mlz4V2FPT0WU
EFO-27	NVXFXI55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTBwNke5O\|kh\|ryP	NWDlc2FHW0GQR1XS
HO-1-N-1	MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7FVXFWUUN3ME2wMlY5ODZ2IN88US=>	NXe3d5ZlW0GQR1XS
TE-5	M2Dxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TrXmlEPTB;MD62PFQxPSEQvF2=	Mkn1V2FPT0WU
EW-22	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPGTWM2OD1yLk[4OFQ1KM7:TR?=	M3zobHNCVkeHUh?=
SW982	M3\nVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVj1Zld1UUN3ME2wMlY5PTBzIN88US=>	MV7TRW5ITVJ?
SF295	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTuSZJOUUN3ME2wMlY5PTB5IN88US=>	MlL1V2FPT0WU
WM-115	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvB[4NnUUN3ME2wMlY5QTJ2IN88US=>	NEf5V2RUSU6JRWK=
COLO-800	M2TEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;Wb5dKSzVyPUCuOlk5OTNizszN	M{LiWHNCVkeHUh?=
NTERA-S-cl-D1	NVzyUpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT5SlZsUUN3ME2wMlcxODZ\|IN88US=>	MmjFV2FPT0WU
NCI-H1648	NYf3emJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkD1TWM2OD1yLkewNVc{KM7:TR?=	MofSV2FPT0WU
NB5	MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLzS3hZUUN3ME2wMlcxOzF7IN88US=>	M3XWPXNCVkeHUh?=
ATN-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHDUZlKSzVyPUCuO\|A2QSEQvF2=	NXnyR\|F6W0GQR1XS
NUGC-3	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHL4N4hKSzVyPUCuO\|A3QTFizszN	NVf5eGg1W0GQR1XS
22RV1	NHPhOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTBwN{C3NVch\|ryP	NGXXeVFUSU6JRWK=
8305C	M4n0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3pT3I4UUN3ME2wMlcxPzV3IN88US=>	MU\TRW5ITVJ?
EFM-19	M3O4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;zVW5KSzVyPUCuO\|A5PDdizszN	M4DsNHNCVkeHUh?=
PC-3	NFKzWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LoNmlEPTB;MD63NlI{KM7:TR?=	M1HXWnNCVkeHUh?=
C32	NYrZTIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnWTWM2OD1yLkeyOFg1KM7:TR?=	MonvV2FPT0WU
MC-IXC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjSTWM2OD1yLkeyO\|E5KM7:TR?=	NWXzT2RQW0GQR1XS
OMC-1	NYLBRWNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHpXlEzUUN3ME2wMlczPzN6IN88US=>	NYm1dGk1W0GQR1XS
HTC-C3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHZTWM2OD1yLkezNVczKM7:TR?=	MoLTV2FPT0WU
RPMI-7951	NYm3ZpR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrEUpJlUUN3ME2wMlc{PTN\|IN88US=>	NHmxVopUSU6JRWK=
AsPC-1	M2r3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHZWpZwUUN3ME2wMlc{Pzl3IN88US=>	NInXe5BUSU6JRWK=
CAKI-1	NVnXeWZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\QTWM2OD1yLke0OlI6KM7:TR?=	NUDlbWd3W0GQR1XS
MHH-PREB-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4D3TmlEPTB;MD63OFc{PiEQvF2=	MoW1V2FPT0WU
HLE	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwN{S4OFQh\|ryP	NVXjbGJZW0GQR1XS
A375	M2e4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rHNWlEPTB;MD63OVE6OyEQvF2=	NEfnOGpUSU6JRWK=
RS4-11	NWHLTWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;XSppKSzVyPUCuO\|U6PDNizszN	M{f0RnNCVkeHUh?=
U-2-OS	NEC5OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofiTWM2OD1yLke1PVch\|ryP	MV7TRW5ITVJ?
NCI-H747	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\RUWlEPTB;MD63OVk6OSEQvF2=	M1PFTXNCVkeHUh?=
NCI-H1623	M{foSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfUW2loUUN3ME2wMlc3OjZzIN88US=>	M3KxbHNCVkeHUh?=
DMS-273	M1m3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnPOo1KSzVyPUCuO\|Y6OjJizszN	NGr6dZVUSU6JRWK=
PSN1	M4S3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHIe5lXUUN3ME2wMlc4ODV5IN88US=>	NHz2SmtUSU6JRWK=
LU-99A	NXT0UlZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjOZ2hUUUN3ME2wMlc4PjR7IN88US=>	MYDTRW5ITVJ?
CAL-12T	NIPFZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTBwN{iwNlkh\|ryP	NX63coN{W0GQR1XS
KYSE-140	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXL0WG9nUUN3ME2wMlc5OTZ6IN88US=>	MVLTRW5ITVJ?
VMRC-RCZ	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PWOGlEPTB;MD63PFQ5OiEQvF2=	NETzT4NUSU6JRWK=
Ca9-22	M4i5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvaXY5KSzVyPUCuO\|g4OzZizszN	MYPTRW5ITVJ?
NCI-H1563	NXrycXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G0VmlEPTB;MD63PFkzPiEQvF2=	MXjTRW5ITVJ?
NCI-H650	M4TQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDKTWM2OD1yLke5NVQ1KM7:TR?=	M1j6fXNCVkeHUh?=
DOHH-2	NVW1NnNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37hWGlEPTB;MD63PVM{KM7:TR?=	M1zadXNCVkeHUh?=
OE33	M1XGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjNTlhKSzVyPUCuO\|k6OTRizszN	MlWxV2FPT0WU
CAL-62	NF;wPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHBTWM2OD1yLke5PVI1KM7:TR?=	MVHTRW5ITVJ?
NCI-H1770	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\pU2lKSzVyPUCuPFAzOSEQvF2=	MoXWV2FPT0WU
SN12C	NVKwNWJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTBwOEC2Olgh\|ryP	NFy0e3ZUSU6JRWK=
HPAF-II	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjhO\|NKSzVyPUCuPFA4QTRizszN	MVvTRW5ITVJ?
SNU-423	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmr3TWM2OD1yLkixOFIzKM7:TR?=	NWf4N2g1W0GQR1XS
A704	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;4fnlKSzVyPUCuPFE4QThizszN	M2HINHNCVkeHUh?=
OVCAR-4	MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTlTWM2OD1yLkixPVEyKM7:TR?=	MV\TRW5ITVJ?
NCI-H2347	NX;BVlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwOEK0NFEh\|ryP	M1jNfHNCVkeHUh?=
OCUB-M	NX7sfHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\Yb2lEPTB;MD64NlY4PSEQvF2=	NGLHVWVUSU6JRWK=
KYSE-450	NG\nNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTBwOEK3NlUh\|ryP	MY\TRW5ITVJ?
PFSK-1	NHmzOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwOEOwN\|kh\|ryP	MkLuV2FPT0WU
A431	M{H3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXDTWM2OD1yLkizNVE3KM7:TR?=	MomwV2FPT0WU
MHH-ES-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnSyTWM2OD1yLkizOFU4KM7:TR?=	MYPTRW5ITVJ?
HD-MY-Z	M1W0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHrZ2VKSzVyPUCuPFQxQTJizszN	MWDTRW5ITVJ?
RT-112	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml6yTWM2OD1yLki0PVM4KM7:TR?=	MlTnV2FPT0WU
KU-19-19	M1PvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m0TGlEPTB;MD64OVEzOSEQvF2=	Mne2V2FPT0WU
HCC1569	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXmNG5yUUN3ME2wMlg2OjB5IN88US=>	NUDDdoJmW0GQR1XS
RPMI-8866	NILuO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrsTWM2OD1yLki1PFIzKM7:TR?=	MkDZV2FPT0WU
CAL-120	NVvtPFF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nCWWlEPTB;MD64OlA1OSEQvF2=	MWnTRW5ITVJ?
CAL-33	M4fsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1K3NWlEPTB;MD64OlQ6PSEQvF2=	MlLmV2FPT0WU
RKO	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\1cnBKSzVyPUCuPFY5OTdizszN	NF:0S29USU6JRWK=
HCC1419	M1v5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTlemR6UUN3ME2wMlg3QTJ6IN88US=>	MlSzV2FPT0WU
CP50-MEL-B	MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzQTWM2OD1yLki4N\|g1KM7:TR?=	MYTTRW5ITVJ?
BPH-1	NYrr[2dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTBwOEizPVUh\|ryP	MW\TRW5ITVJ?
SF126	M4[yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjnV3RKSzVyPUCuPFg4OTRizszN	NEXLWnpUSU6JRWK=
BHY	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFW1RmlKSzVyPUCuPFg4OzRizszN	MYPTRW5ITVJ?
BxPC-3	NHLOVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjYXJNKSzVyPUCuPFg5OzNizszN	NWPjWYlkW0GQR1XS
ETK-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjKV\|Q5UUN3ME2wMlg6Ozd{IN88US=>	NXXLT5FYW0GQR1XS
NCI-H1573	M2Hs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHLUFVCUUN3ME2wMlkxOjJ7IN88US=>	M4jEeXNCVkeHUh?=
C-33-A	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnQSJNKSzVyPUCuPVA1PDJizszN	MkK1V2FPT0WU
UACC-893	NWO4V3ljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vSO2lEPTB;MD65Nlg2PSEQvF2=	MmDXV2FPT0WU
RXF393	NGDSWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTEbYtQUUN3ME2wMlkzQDl5IN88US=>	M4DMeHNCVkeHUh?=
MIA-PaCa-2	M1m1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jpWGlEPTB;MD65NlkzOiEQvF2=	NWi3do43W0GQR1XS
HCC1806	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[0VmlEPTB;MD65N\|I2PiEQvF2=	MnnMV2FPT0WU
DMS-114	NYPmSGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfHfmR3UUN3ME2wMlk{Pjd5IN88US=>	NX3vfoJlW0GQR1XS
MOLT-16	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3:xNGlEPTB;MD65N\|g1PSEQvF2=	M2CxVHNCVkeHUh?=
ACN	NEi1bm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTBwOUSyO\|ch\|ryP	NIfVWZZUSU6JRWK=
SNU-449	NXv3fYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEj1W4xKSzVyPUCuPVU6OjRizszN	MUTTRW5ITVJ?
A427	M1HVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnCTWM2OD1yLkm2NVk5KM7:TR?=	NHrVOGVUSU6JRWK=
DEL	M3TVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fpU2lEPTB;MD65Olc4OyEQvF2=	M3\w[nNCVkeHUh?=
NCI-H1792	NHLQfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3wVnZKSzVyPUCuPVcyODFizszN	MknsV2FPT0WU
A2058	NXW1cnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrwfpJpUUN3ME2wMlk4OzZizszN	MXzTRW5ITVJ?
SW13	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTBwOUizPVIh\|ryP	NFfBWIpUSU6JRWK=
T98G	MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\2OmlEPTB;MT6wNVM3PCEQvF2=	MWjTRW5ITVJ?
LU-134-A	NFXMXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLoTWM2OD1zLkCyOlc2KM7:TR?=	Ml7zV2FPT0WU
GI-ME-N	NYfCbYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O4XmlEPTB;MT6wNlgzPyEQvF2=	MlzCV2FPT0WU
D-423MG	MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmC1TWM2OD1zLkCyPVY{KM7:TR?=	MV;TRW5ITVJ?
PANC-03-27	M{TPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mor4TWM2OD1zLkCzNVQyKM7:TR?=	MmLCV2FPT0WU
P12-ICHIKAWA	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWflWIluUUN3ME2xMlA{PDB4IN88US=>	NG\wd2VUSU6JRWK=
SCH	NHPnPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TxPWlEPTB;MT6wN\|Q2KM7:TR?=	MVfTRW5ITVJ?
D-566MG	NITKW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFwME[3NlYh\|ryP	MmLGV2FPT0WU
OS-RC-2	NF7UO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrEcFlbUUN3ME2xMlA4QTRizszN	MXTTRW5ITVJ?
KOSC-2	NILzfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzPOphyUUN3ME2xMlA5ODJzIN88US=>	NEjuTHVUSU6JRWK=
SH-4	M{D5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTFwMEi0N\|Eh\|ryP	MkewV2FPT0WU
786-0	M4PNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTFwMEi5N\|Qh\|ryP	NYT6[lFRW0GQR1XS
Mewo	NED3c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTFwMEmyOFgh\|ryP	MXrTRW5ITVJ?
AGS	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvSTWM2OD1zLkC5OFU6KM7:TR?=	NGnOWY9USU6JRWK=
Daoy	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILhW2ZKSzVyPUGuNFk3OjhizszN	M4fLRXNCVkeHUh?=
SW48	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\CTWM2OD1zLkGwPVEyKM7:TR?=	M1rQTnNCVkeHUh?=
KYSE-180	M1XEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFwMUGwNlEh\|ryP	MoPHV2FPT0WU
NH-12	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfMZWZKSzVyPUGuNVEzOzdizszN	Mkn1V2FPT0WU
BE-13	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TiRWlEPTB;MT6xNVc2QSEQvF2=	NGXVdoJUSU6JRWK=
ES3	NITwcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDOXW9KSzVyPUGuNVMyPzFizszN	MWPTRW5ITVJ?
NCI-H1092	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XwVmlEPTB;MT6xN\|Qh\|ryP	MmX1V2FPT0WU
NCI-H1755	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\TTmlEPTB;MT6xN\|k1OSEQvF2=	NXPiVI01W0GQR1XS
EKVX	NIXwOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{D0TGlEPTB;MT6xOFAxOSEQvF2=	MVfTRW5ITVJ?
NB13	M4jQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDlbpBzUUN3ME2xMlE1PDVizszN	NELpZ45USU6JRWK=
NCI-H2405	NWrUNml2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nkSmlEPTB;MT6xOFU4PCEQvF2=	NWDmeYs1W0GQR1XS
LS-411N	NGjnUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vxWWlEPTB;MT6xOVAyPyEQvF2=	NVrlXHk{W0GQR1XS
MDA-MB-453	M{X0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPRTWM2OD1zLkG1OlI1KM7:TR?=	M4XDN3NCVkeHUh?=
SCC-15	NIP0PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr0SIVKSzVyPUGuNVY6PTZizszN	M3P4[XNCVkeHUh?=
C2BBe1	NFvT[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7uTWM2OD1zLkG3NFU3KM7:TR?=	NFLMd3pUSU6JRWK=
HT-144	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFwMUewO{DPxE1?	M3XH[HNCVkeHUh?=
HEC-1	NGnOPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFwMUe2Nlch\|ryP	MWHTRW5ITVJ?
HCE-T	NEexSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTod2hEUUN3ME2xMlE4QTh\|IN88US=>	NVHJRlB1W0GQR1XS
IST-MEL1	NWP3[YJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjTTWM2OD1zLkG5NFgzKM7:TR?=	Mlv1V2FPT0WU
Detroit562	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFwMUm0N\|kh\|ryP	NHLRc4dUSU6JRWK=
A4-Fuk	NIXD[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFwMkC0OFEh\|ryP	MlHUV2FPT0WU
HDLM-2	NFLJcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPxV2pKSzVyPUGuNlE{OjZizszN	NFTQbGdUSU6JRWK=
MKN7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3T5c2lEPTB;MT6yNVcxOiEQvF2=	MUPTRW5ITVJ?
MDA-MB-415	M3G2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPZTWM2OD1zLkKxO\|AzKM7:TR?=	NGXhZmZUSU6JRWK=
BT-20	M3nnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIX2XJBKSzVyPUGuNlI1PDRizszN	NWjCXHROW0GQR1XS
NCI-H2030	NH;wUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTrTWM2OD1zLkK0NVA3KM7:TR?=	MoW1V2FPT0WU
LS-123	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnQW\|ZDUUN3ME2xMlI1PzV\|IN88US=>	NFTZRW1USU6JRWK=
SK-MEL-3	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DoTmlEPTB;MT6yOFc4PiEQvF2=	MVHTRW5ITVJ?
KS-1	M1jSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnG5TWM2OD1zLkK1NVcyKM7:TR?=	NFrF[YZUSU6JRWK=
LU-65	NYGxVY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTFwMkW2NFYh\|ryP	M3\TN3NCVkeHUh?=
NCI-H596	NGLyZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIL1RoFKSzVyPUGuNlU6OjlizszN	Mn7PV2FPT0WU
KYSE-410	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\RTWM2OD1zLkK3NFE1KM7:TR?=	NV7qS49RW0GQR1XS
NCI-H2228	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3P5c2lEPTB;MT6yO\|E3PyEQvF2=	NF74R2hUSU6JRWK=
LN-405	NGfVRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwMkiwNlEh\|ryP	NVS2T2tTW0GQR1XS
8505C	M3y3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17VVGlEPTB;MT6yPFgzOyEQvF2=	NXfXVldMW0GQR1XS
BFTC-909	NFjXcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofpTWM2OD1zLkK5OFM1KM7:TR?=	Mm[2V2FPT0WU
OC-314	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrkTWM2OD1zLkK5PVI6KM7:TR?=	Ml;XV2FPT0WU
NMC-G1	MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnEdY9KSzVyPUGuN\|EyOzVizszN	M{TRW3NCVkeHUh?=
SKG-IIIa	NVm3bGx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXyTWM2OD1zLkOxOFI5KM7:TR?=	M3LFRXNCVkeHUh?=
GAK	NGHROVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XXW2lEPTB;MT6zNVg2QCEQvF2=	M3vlNHNCVkeHUh?=
D-263MG	M1HQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7kTWM2OD1zLkOyOlQyKM7:TR?=	NX\xWnoyW0GQR1XS
NCI-H446	NF7pdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle2TWM2OD1zLkOyPVAzKM7:TR?=	NFyweolUSU6JRWK=
TGBC1TKB	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnteZhKSzVyPUGuN\|I6QThizszN	MYDTRW5ITVJ?
GCT	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTFwM{SzOFUh\|ryP	MXnTRW5ITVJ?
COR-L23	NIG4OoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DkSmlEPTB;MT6zOFg1PSEQvF2=	MUjTRW5ITVJ?
TK10	NVi5PVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvDTWM2OD1zLkO1O\|k4KM7:TR?=	MWrTRW5ITVJ?
ES6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFwM{[zO\|Yh\|ryP	MnO1V2FPT0WU
SW1088	M3rpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFwM{[2NVIh\|ryP	NIDYSIhUSU6JRWK=
AM-38	M1SxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTFwM{exPVkh\|ryP	M{G3eHNCVkeHUh?=
CHP-134	NHnuOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwM{e4OFQh\|ryP	MmHGV2FPT0WU
SW872	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\ETZpKSzVyPUGuN\|g2PTVizszN	MlTLV2FPT0WU
LB831-BLC	NHziclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3FRZpKSzVyPUGuN\|kxPjdizszN	MmrjV2FPT0WU
TE-12	NY\6NGt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFwNEC2NFEh\|ryP	NEL5dYtUSU6JRWK=
LCLC-97TM1	M2nmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEm4VldKSzVyPUGuOFExPDZizszN	NYP1flBFW0GQR1XS
HCT-116	NHfhO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTFwNEK4OVQh\|ryP	MWXTRW5ITVJ?
ALL-PO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1iwVGlEPTB;MT60N\|c4PCEQvF2=	NGLCSYhUSU6JRWK=
EW-16	NWe1[Is1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j1UmlEPTB;MT60N\|g1OiEQvF2=	NUjyXZZpW0GQR1XS
NCI-H661	MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoH0TWM2OD1zLkS0O\|c2KM7:TR?=	NHfw[WRUSU6JRWK=
TE-8	M2rkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTFwNEW1OkDPxE1?	MYXTRW5ITVJ?
TCCSUP	Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoezTWM2OD1zLkS2PVYh\|ryP	NI\kfVRUSU6JRWK=
SW1990	NIfKOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFwNEe1N\|Mh\|ryP	M{LXWHNCVkeHUh?=
UM-UC-3	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjETpNKSzVyPUGuOFc3PzVizszN	M2PN[3NCVkeHUh?=
HuP-T4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrRXlQ5UUN3ME2xMlQ5PjB5IN88US=>	M2XsRnNCVkeHUh?=
NCI-H1299	M3G1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHYdHlKSzVyPUGuOVAxQDZizszN	M{f5bHNCVkeHUh?=
RO82-W-1	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUf4SXM{UUN3ME2xMlUzODhzIN88US=>	NEHBUYpUSU6JRWK=
Becker	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTFwNUKxPFch\|ryP	M4nzZ3NCVkeHUh?=
SNU-387	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\YSnFKSzVyPUGuOVIzPDFizszN	MVzTRW5ITVJ?
CAL-85-1	MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHITWM2OD1zLkWyOVk6KM7:TR?=	M2TJU3NCVkeHUh?=
647-V	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTFwNUO4PEDPxE1?	NXrJOGRUW0GQR1XS
SBC-5	NFPBUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLo[ng2UUN3ME2xMlU1PTl\|IN88US=>	NX3Oe\|llW0GQR1XS
NCI-H23	M1PEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1qx[mlEPTB;MT61OVcyPCEQvF2=	NV7pRo5{W0GQR1XS
CGTH-W-1	NUfqcmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTFwNUW4NVkh\|ryP	MYXTRW5ITVJ?
SK-N-FI	NEDjeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonZTWM2OD1zLkW1PVA5KM7:TR?=	MkHlV2FPT0WU
KM-H2	NWjVZ5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnK[mIzUUN3ME2xMlU3PDd2IN88US=>	NEH3[HlUSU6JRWK=
KY821	M{D6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfuN3hKSzVyPUGuOVY3OTdizszN	M{\m[HNCVkeHUh?=
RH-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXiyNo9SUUN3ME2xMlU3PzZ{IN88US=>	MmiyV2FPT0WU
KYSE-270	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwNUe0NlMh\|ryP	MYTTRW5ITVJ?
SF539	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnkRXJKSzVyPUGuOVc6PjlizszN	NG\OZndUSU6JRWK=
JEG-3	NYTmcVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTFwNUiwPVQh\|ryP	MoLHV2FPT0WU
SCC-25	NYnDT3ByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfpNVZKSzVyPUGuOVg1OzJizszN	NFXodVJUSU6JRWK=
SW1573	NX;I[XI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfPTWM2OD1zLk[wNVU5KM7:TR?=	M1HHOXNCVkeHUh?=
EW-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\GbXFJUUN3ME2xMlYyOzVzIN88US=>	MYrTRW5ITVJ?
YKG-1	M3jrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HBUWlEPTB;MT62NVQ{QCEQvF2=	MmDsV2FPT0WU
EW-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3ocYRyUUN3ME2xMlYyPzRzIN88US=>	NX3Sb2dCW0GQR1XS
DJM-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrWTWM2OD1zLk[xPFI2KM7:TR?=	M1\TS3NCVkeHUh?=
Calu-3	NYfYTHRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTkS2M{UUN3ME2xMlY2OjF\|IN88US=>	MlLZV2FPT0WU
HT-3	M2P0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGKwN4xKSzVyPUGuOlU3PiEQvF2=	NGS1N2pUSU6JRWK=
NCI-H69	NFTPSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnzWZlOUUN3ME2xMlY4OzR\|IN88US=>	MXrTRW5ITVJ?
NCI-H2126	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnweIJKSzVyPUGuOlc4QTdizszN	MlSzV2FPT0WU
RPMI-2650	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTFwNkizNVch\|ryP	MknTV2FPT0WU
TE-6	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfYXYN{UUN3ME2xMlcxQDd2IN88US=>	NWCyXmdEW0GQR1XS
MDA-MB-231	M4PvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTFwN{G5PVMh\|ryP	Mnn4V2FPT0WU
A2780	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHlbJVXUUN3ME2xMlczOjB5IN88US=>	Mn;pV2FPT0WU
GOTO	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTFwN{O1OkDPxE1?	NXnlbYJtW0GQR1XS
KYSE-70	M1W5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\KXWlEPTB;MT63OFQ1OiEQvF2=	MXLTRW5ITVJ?
GMS-10	NVzGVXBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTFwN{S2OlIh\|ryP	M{iwOnNCVkeHUh?=
CaR-1	NYKxfYYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfpNFl2UUN3ME2xMlc1QDF{IN88US=>	NV7hR\|VyW0GQR1XS
SW900	NH\JNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLGbG0yUUN3ME2xMlc1QTl\|IN88US=>	MUDTRW5ITVJ?
BB49-HNC	NWfnNHNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTXTWM2OD1zLke1NVY5KM7:TR?=	Mle0V2FPT0WU
SNB75	NEH2cXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PNcGlEPTB;MT63OVQ6OiEQvF2=	M3;xVHNCVkeHUh?=
SK-PN-DW	NVvGVYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFwN{W2PFIh\|ryP	NVPHSHRFW0GQR1XS
5637	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwN{eyOlgh\|ryP	NU\nOmltW0GQR1XS
BT-474	NXTZdYoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvySGNKSzVyPUGuO\|gyPzFizszN	M{TDeHNCVkeHUh?=
KM12	NWTTcW01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnFTWM2OD1zLke5O\|QyKM7:TR?=	MoC5V2FPT0WU
COLO-680N	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3[xTGlEPTB;MT64NlM5OSEQvF2=	MojMV2FPT0WU
Saos-2	NFTsOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3G2OGlEPTB;MT64NlQ1PSEQvF2=	NWXtTW1tW0GQR1XS
CAL-54	NV[2Omd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vy[WlEPTB;MT64N\|MyOyEQvF2=	NIrvelBUSU6JRWK=
U-118-MG	NYjxXohPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUKxWodxUUN3ME2xMlg1PjJ{IN88US=>	M3XLbHNCVkeHUh?=
TGBC24TKB	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrpTWM2OD1zLki1OVAyKM7:TR?=	MnOyV2FPT0WU
NCI-H2052	NIDGV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\MWlFiUUN3ME2xMlg3PDFizszN	NVHzW5JOW0GQR1XS
BB30-HNC	M4fhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTFwOE[0OlIh\|ryP	MlX4V2FPT0WU
KNS-81-FD	NX;hWnhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHRUXlWUUN3ME2xMlg6OTZ3IN88US=>	Mmm1V2FPT0WU
HN	NXLCVlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorTTWM2OD1zLki5OVQ2KM7:TR?=	MYrTRW5ITVJ?
ACHN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHNNJE5UUN3ME2xMlkxPzh4IN88US=>	M3jpWXNCVkeHUh?=
HSC-2	NHzqN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr5fHVKSzVyPUGuPVExQTZizszN	M{\oT3NCVkeHUh?=
HCC2998	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTFwOUOzNlUh\|ryP	MlrIV2FPT0WU
HEL	NFrTcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\jfI9KSzVyPUGuPVQyQDRizszN	NYXxTZlxW0GQR1XS
SW684	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlW0TWM2OD1zLkm3N\|cyKM7:TR?=	M1vzXnNCVkeHUh?=
NCI-H1693	NWCwVHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTVTWM2OD1zLkm4NFg3KM7:TR?=	MVzTRW5ITVJ?
8-MG-BA	NHPFdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk[0TWM2OD1zLkm4NlEh\|ryP	NGnae\|NUSU6JRWK=
OVCAR-8	M{\EPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjlT2hKSzVyPUKuNFAzQTVizszN	MoT4V2FPT0WU
DSH1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\OOZVpUUN3ME2yMlAyPzd2IN88US=>	NXjMe4piW0GQR1XS
KYSE-520	M3Kwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPNcI51UUN3ME2yMlAzODR7IN88US=>	NFyyV2dUSU6JRWK=
GB-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvwTWM2OD1{LkCyOVc4KM7:TR?=	NXfR[JBwW0GQR1XS
RCC10RGB	M2rOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDFTWM2OD1{LkC0PFcyKM7:TR?=	MY\TRW5ITVJ?
SW954	NGO3XpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4L0ZWlEPTB;Mj6wOVA{PiEQvF2=	NUjJVZJ4W0GQR1XS
IST-MES1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV21[opCUUN3ME2yMlA2PTZ6IN88US=>	NYHnXWVtW0GQR1XS
AU565	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PCcGlEPTB;Mj6wOVkxPSEQvF2=	NF\Kc\|RUSU6JRWK=
CW-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\IUItKSzVyPUKuNFY5PzVizszN	NYLD[nl5W0GQR1XS
TE-1	NXjq[HN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWezR\|dUUUN3ME2yMlA6Ozd5IN88US=>	Mn;YV2FPT0WU
KP-4	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTJwMUCzNVIh\|ryP	MkPVV2FPT0WU
SNU-C2B	NWW1cFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTJwMUC4NlMh\|ryP	NHj6eWdUSU6JRWK=
NCI-H1395	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTJwMUC5PFYh\|ryP	NFLZemRUSU6JRWK=
CAS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4THV2lEPTB;Mj6xNVU1PiEQvF2=	M1rhe3NCVkeHUh?=
NCI-H1155	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPoTWM2OD1{LkKyOlkh\|ryP	NYrlbpM1W0GQR1XS
SK-MEL-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjIXJhuUUN3ME2yMlI5OThzIN88US=>	Mn;2V2FPT0WU
KINGS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXu5dlJpUUN3ME2yMlMxODh6IN88US=>	MnXpV2FPT0WU
ESS-1	NEHLblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfuWZgxUUN3ME2yMlMxPTFizszN	MYjTRW5ITVJ?
PANC-10-05	NW\yb4lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;vUo9SUUN3ME2yMlM4ODJ2IN88US=>	MXjTRW5ITVJ?
HT-1376	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vRNWlEPTB;Mj6zPFcxQCEQvF2=	NIrPbItUSU6JRWK=
LS-513	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fJdGlEPTB;Mj6zPFg4PCEQvF2=	M{jqPHNCVkeHUh?=
KNS-42	NEL4c\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;IWnFKSzVyPUKuN\|kyODVizszN	MkTkV2FPT0WU
639-V	M3\HdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XMZWlEPTB;Mj60Nlc2QCEQvF2=	NGHo[VVUSU6JRWK=
SJRH30	NICzW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVO1[ZpWUUN3ME2yMlQ2OTZzIN88US=>	MmG0V2FPT0WU
SW1783	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzkTWM2OD1{LkS3NFc5KM7:TR?=	M{HNSXNCVkeHUh?=
NB6	M3nvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkX1TWM2OD1{LkS4Nlgh\|ryP	MoT2V2FPT0WU
SK-MEL-30	NIHPenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnxXIhpUUN3ME2yMlQ5QDNizszN	M4m5XXNCVkeHUh?=
HCE-4	M{PkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3uwdWlEPTB;Mj60PVQxOiEQvF2=	M4GwS3NCVkeHUh?=
NB10	NUHsbYZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NID5c5dKSzVyPUKuOFk1OjlizszN	Mo\HV2FPT0WU
H-EMC-SS	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEizUXlKSzVyPUKuOVQ3PSEQvF2=	MYTTRW5ITVJ?
SK-HEP-1	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LCdmlEPTB;Mj61OVI{PiEQvF2=	NUj6cXlbW0GQR1XS
HCC1395	NVPL[ldZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmToTWM2OD1{LkW1OlU2KM7:TR?=	M{PUWnNCVkeHUh?=
HuCCT1	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2CxcWlEPTB;Mj61OlM6KM7:TR?=	NEXpUJpUSU6JRWK=
SiHa	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvKTWM2OD1{LkW4O\|E6KM7:TR?=	MXXTRW5ITVJ?
EFO-21	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJwNUi3OlQh\|ryP	M{nZb3NCVkeHUh?=
NCI-H1666	NILtSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTJwNUmwO\|Yh\|ryP	M4izZnNCVkeHUh?=
UMC-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWm4XI93UUN3ME2yMlU6QDZ6IN88US=>	MXHTRW5ITVJ?
COLO-679	NFvMSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXzZZJTUUN3ME2yMlYyOjN\|IN88US=>	MXPTRW5ITVJ?
A388	NVnZcINCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3UN5M2UUN3ME2yMlY2OjV\|IN88US=>	NUj2e41sW0GQR1XS
LB2518-MEL	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzzRpBKUUN3ME2yMlY2PDB6IN88US=>	NXv3[GNxW0GQR1XS
EW-13	Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXlb25KSzVyPUKuOlg4PjhizszN	MXnTRW5ITVJ?
MLMA	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTJwNki4OVYh\|ryP	M2TERXNCVkeHUh?=
HOP-92	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHNTWM2OD1{LkewNVEh\|ryP	MU\TRW5ITVJ?
NOMO-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TCdmlEPTB;Mj63NVQ1OiEQvF2=	NFPWZmlUSU6JRWK=
NCI-H810	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTXcpV[UUN3ME2yMlczOTl6IN88US=>	Mn7NV2FPT0WU
769-P	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3frcmlEPTB;Mj63NlI5KM7:TR?=	MlPjV2FPT0WU
SAS	NEG2R2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M371SWlEPTB;Mj63OlUh\|ryP	M3rHe3NCVkeHUh?=
M059J	NW\QSmZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJwN{izNVgh\|ryP	NUPZRXdKW0GQR1XS
RD	M4jyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPjNVJ2UUN3ME2yMlc6PDdzIN88US=>	NFPmNnJUSU6JRWK=
GT3TKB	NGC4XWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i3ZmlEPTB;Mj64N\|Q{OyEQvF2=	M3nLcnNCVkeHUh?=
MZ7-mel	M2rhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITpXXlKSzVyPUKuPFY2ODJizszN	MU\TRW5ITVJ?
KYSE-510	M{XkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTJwOEm1NFQh\|ryP	M3XifnNCVkeHUh?=
NCI-N87	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJwOUG4NFch\|ryP	M1nYN3NCVkeHUh?=
MKN1	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPZ[JZFUUN3ME2zMlAxOTZ\|IN88US=>	MYLTRW5ITVJ?
NCI-H2170	NFXVSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHqT3I{UUN3ME2zMlAxPDVzIN88US=>	MYLTRW5ITVJ?
OVCAR-3	NGXUO\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTNwMEKxNVUh\|ryP	Ml31V2FPT0WU
KLE	NYG2XodnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2C1cmlEPTB;Mz6wOlgyOiEQvF2=	M4jzTXNCVkeHUh?=
LB771-HNC	NYfmc2RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFOyTmRKSzVyPUOuNFk{PDNizszN	NXXST\|F5W0GQR1XS
MC116	NWiwbYZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLRbI5tUUN3ME2zMlEyOTF{IN88US=>	NH7vdYpUSU6JRWK=
SCC-9	NVHpVFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnDTWM2OD1\|LkGxN\|Y3KM7:TR?=	MXLTRW5ITVJ?
U031	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTNwMUK0NlMh\|ryP	M2Dz[HNCVkeHUh?=
LCLC-103H	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTNwMkO4PVQh\|ryP	NXr3XmxpW0GQR1XS
U-266	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4mz[mlEPTB;Mz6yO\|Y{OyEQvF2=	MXzTRW5ITVJ?
JVM-2	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTNwM{KxOlQh\|ryP	MoHyV2FPT0WU
UACC-257	NF:4SHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTNwNE[0N\|Eh\|ryP	MlXZV2FPT0WU
LB996-RCC	NITIbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTNwNE[1NFIh\|ryP	M{fyW3NCVkeHUh?=
BT-549	NEKzZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPQWHNZUUN3ME2zMlUxOjB7IN88US=>	MVfTRW5ITVJ?
NCI-H526	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHiTWM2OD1\|LkW0NVU5KM7:TR?=	NGHFfJVUSU6JRWK=
RH-18	MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13SXGlEPTB;Mz62NVc6QCEQvF2=	NGCxSlVUSU6JRWK=
SW626	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TTUmlEPTB;Mz63NVEzQCEQvF2=	MojZV2FPT0WU
SK-N-AS	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUT0T3RRUUN3ME2zMlc{OjR5IN88US=>	M1\nc3NCVkeHUh?=
IGR-1	NXPvbWZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XGW2lEPTB;Mz63OFI1QCEQvF2=	M2f3cXNCVkeHUh?=
NCI-H2291	M2TPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTNwN{WzN\|Yh\|ryP	M4\MdXNCVkeHUh?=
NCI-H441	NXfLN3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\oTWM2OD1\|LkiyOFM{KM7:TR?=	M3LSfHNCVkeHUh?=
D-247MG	NHP0e49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3S0V2lEPTB;Mz64OlA{OSEQvF2=	MWLTRW5ITVJ?
COLO-320-HSR	NYDLdYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\UZmlEPTB;Mz65NVI4OSEQvF2=	NXTC[\|l[W0GQR1XS
A253	M1\ZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7tO2lKSzVyPUOuPVE1OzZizszN	M4XNSHNCVkeHUh?=
HT55	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVq5UpNJUUN3ME2zMlkyPzd\|IN88US=>	NUfwOYtjW0GQR1XS
MZ1-PC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLqTWM2OD1\|Lkm1PFY1KM7:TR?=	M3\CW3NCVkeHUh?=
RERF-LC-MS	NX;NR4J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmeyTWM2OD1\|Lkm2OVI2KM7:TR?=	MmTpV2FPT0WU
SF268	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2KxOGlEPTB;ND6xNlg5OSEQvF2=	M2PLZnNCVkeHUh?=
RMG-I	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTiXYJKSzVyPUSuNlE1PTRizszN	MXfTRW5ITVJ?
CFPAC-1	NIGxZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HpTmlEPTB;ND6yNVY5PSEQvF2=	NWLYdHJ6W0GQR1XS
S-117	NE\1V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFj3dJZKSzVyPUSuNlIxOjRizszN	MVXTRW5ITVJ?
NCI-H2122	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXYb5ZkUUN3ME20MlMxQTNzIN88US=>	MUjTRW5ITVJ?
J82	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;1XmlEPTB;ND6zN\|Q1OSEQvF2=	NYjyTW1MW0GQR1XS
CAL-72	M2LsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jsPWlEPTB;ND6zOVQ4PyEQvF2=	NFr4SG5USU6JRWK=
GP5d	NG\iPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYThWmdFUUN3ME20MlQyOjl6IN88US=>	NFqzTFlUSU6JRWK=
UACC-62	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTHfZNqUUN3ME20MlQ3PTR3IN88US=>	NXnHUoc1W0GQR1XS
MS-1	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfwSHlKSzVyPUSuOFkyOTVizszN	M3;MOHNCVkeHUh?=
RCM-1	NFS1eHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTRwNUK5NkDPxE1?	MWnTRW5ITVJ?
IST-SL1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3NfnRKSzVyPUSuOlU{PTlizszN	MnXoV2FPT0WU
SW756	NXex[mdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XjT2lEPTB;ND62PVE{PSEQvF2=	MmjoV2FPT0WU
HCC38	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XTfGlEPTB;ND63NVE6PyEQvF2=	MmjFV2FPT0WU
YAPC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnuVZVKSzVyPUSuO\|E{OTNizszN	M4nV[HNCVkeHUh?=
DK-MG	M3zZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTRwN{ixNVIh\|ryP	NH7rUnpUSU6JRWK=
HCC1937	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\IW49KSzVyPUSuPFUyOjVizszN	NITUT29USU6JRWK=
OAW-28	NHPjNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPOUWlKSzVyPUSuPVI1OzVizszN	MXzTRW5ITVJ?
MEG-01	M2W5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLkTWM2OD13LkC4N\|I5KM7:TR?=	M1PnZnNCVkeHUh?=
GI-1	NYHQc2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTVwMkO0PFYh\|ryP	MY\TRW5ITVJ?
FADU	NILBPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTVwMke4N\|ch\|ryP	MkP3V2FPT0WU
CAPAN-1	M4LzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DvSGlEPTB;NT6zPVQ{OiEQvF2=	MnPPV2FPT0WU
TGBC11TKB	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTVwNEW3PFYh\|ryP	NVPWeVFwW0GQR1XS
DBTRG-05MG	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\FPHNKSzVyPUWuOVA2OiEQvF2=	MoXTV2FPT0WU
ONS-76	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTVwNUW4NFEh\|ryP	Mke3V2FPT0WU
Ca-Ski	MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\YWmlEPTB;NT62NlU3PiEQvF2=	M3rpPXNCVkeHUh?=
COLO-741	MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7ZNIw5UUN3ME21MlcyQTl3IN88US=>	MYrTRW5ITVJ?
HT-29	NHrLdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDjTWM2OD13LkiwOFc2KM7:TR?=	NWHoSpVwW0GQR1XS
HCC1187	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFWzRXdKSzVyPUWuPFExODhizszN	Ml7IV2FPT0WU
Capan-2	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHuzeWlKSzVyPUWuPVU6QTRizszN	NXK0clc5W0GQR1XS
NCI-H630	NX;WZ\|I5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHqzWHJKSzVyPU[uNVE1PDFizszN	MXvTRW5ITVJ?
COLO-678	NEm4dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnKU3NKSzVyPU[uNVUxQTJizszN	Mn7EV2FPT0WU
D-502MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\nTWM2OD14LkG3N\|M3KM7:TR?=	MYPTRW5ITVJ?
NB17	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;MTWM2OD14LkK0PVQ{KM7:TR?=	MX3TRW5ITVJ?
SK-MEL-24	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fYPWlEPTB;Nj6yOlQ6KM7:TR?=	NX;sO5MxW0GQR1XS
NCI-SNU-5	M3;VeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3NTWM2OD14LkK3NVE5KM7:TR?=	MmHaV2FPT0WU
D-392MG	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHNdXE3UUN3ME22MlM{Ozl7IN88US=>	NE\YZXNUSU6JRWK=
A498	NISzVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTZwNECzNFIh\|ryP	MWLTRW5ITVJ?
OCI-AML2	M1\lO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWiwXYxUUUN3ME22MlQ2PDR3IN88US=>	NFjWcZZUSU6JRWK=
HCC2157	NHPiRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTZwNEW2NVYh\|ryP	NILMU2hUSU6JRWK=
C3A	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTZwNUKwNFQh\|ryP	NUfkZW9OW0GQR1XS
NCI-H1650	MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTZwN{C1NlIh\|ryP	MU\TRW5ITVJ?
DU-145	NVLkWJhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHRTWM2OD14Lke3NFMh\|ryP	MXfTRW5ITVJ?
COLO-829	NW\nToZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3O0XWlEPTB;Nj63O\|g4OyEQvF2=	MXfTRW5ITVJ?
LS-1034	NF;pdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1yzcmlEPTB;Nz6wOFQyOiEQvF2=	M37DcXNCVkeHUh?=
HCC1954	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXweHpKSzVyPUeuOFgyOzRizszN	NU\6T\|lsW0GQR1XS
KURAMOCHI	M3raT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7zXmNXUUN3ME23MlQ5PTN\|IN88US=>	MofPV2FPT0WU
Mo-T	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTdwNUG0PVgh\|ryP	NY\VXlBLW0GQR1XS
OE19	M1XvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3ucXdKSzVyPUeuOlU2ODNizszN	NWnKd29QW0GQR1XS
COR-L105	NXfINlloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTdwN{G0NlEh\|ryP	M1q0SXNCVkeHUh?=
NCI-H2342	M2rZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Pr[mlEPTB;Nz63NVUzOSEQvF2=	NFziWZhUSU6JRWK=
U-87-MG	M1S4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDy[ldKSzVyPUiuNFM{OzRizszN	MkewV2FPT0WU
MKN28	M4joRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLxTWM2OD16LkGxOVE2KM7:TR?=	MlfjV2FPT0WU
HT-1197	NXPqbHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHwbVZ5UUN3ME24MlI2QTB5IN88US=>	MkHhV2FPT0WU
ChaGo-K-1	NGfYd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jBSmlEPTB;OD6zOFI1PSEQvF2=	MnO0V2FPT0WU
NCI-H226	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4S5VmlEPTB;OD60OFM{OSEQvF2=	NGH4b5dUSU6JRWK=
NCI-H2029	MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmW1TWM2OD17LkC2O\|U6KM7:TR?=	MYTTRW5ITVJ?
TE-11	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LONWlEPTB;OT60OVU5QCEQvF2=	MXjTRW5ITVJ?
ZR-75-30	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGq3c4hKSzVyPUmuPVI3OzRizszN	MVPTRW5ITVJ?
SW837	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfjTWM2OD1zMD6yNlk{KM7:TR?=	NVy3[o1jW0GQR1XS
NCI-H1651	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnxTWM2OD1zMD6yN\|I3KM7:TR?=	MYXTRW5ITVJ?
NCI-H727	NGDBeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHwTWM2OD1zMD60OFk2KM7:TR?=	MnvWV2FPT0WU
NCI-H358	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPHT5JKSzVyPUGwMlg{PjVizszN	MlvnV2FPT0WU
NCI-H2087	NFnwe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TMbWlEPTB;MUGuNFQ{PCEQvF2=	MojyV2FPT0WU
FTC-133	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4O0fWlEPTB;MUGuOFA2OSEQvF2=	NGSxTWlUSU6JRWK=
LAN-6	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD0bZVpUUN3ME2xNk4yOjRizszN	NYTQUHZQW0GQR1XS
NCI-H1838	M4n1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LIV2lEPTB;MUKuOVE2OSEQvF2=	NHviWJJUSU6JRWK=
Calu-6	NFHCT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTF2LkGwNlEh\|ryP	NWHpXI1oW0GQR1XS
HCC70	M1rGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUH1SI9JUUN3ME2xOE41PTFizszN	MVvTRW5ITVJ?
KARPAS-299	M3TkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHsTWM2OD1zNT6yNVU6KM7:TR?=	MXnTRW5ITVJ?
CAL-27	NGTyboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTF3LkO4OFMh\|ryP	M4\4cnNCVkeHUh?=
NCI-H82	NY\R[4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3ZTWM2OD1zNT61N\|Ih\|ryP	MXfTRW5ITVJ?
no-10	NY\KPW9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTF3LkmzPEDPxE1?	NWLxTJU{W0GQR1XS
U251	NHvocpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvMZZNCUUN3ME2xOk4{Pjd3IN88US=>	MWPTRW5ITVJ?
TE-9	NWXkeGtKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7XTWM2OD1zNz61NVY3KM7:TR?=	M4\peHNCVkeHUh?=
TE-10	M3H1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDofWFKSzVyPUG5MlA3ODdizszN	NUP2cVU5W0GQR1XS
COLO-824	M4fHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYP5R3c6UUN3ME2yNE46Ojd4IN88US=>	NWC4Oo1JW0GQR1XS
HuP-T3	NGfnZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLxTWM2OD1{MT6wO\|Q5KM7:TR?=	M4\UdnNCVkeHUh?=
KALS-1	NVryNVZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJzLkG3OUDPxE1?	MWnTRW5ITVJ?
L-428	NWjGW2xHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVK3R4x1UUN3ME2yNU41ODF4IN88US=>	MU\TRW5ITVJ?
JAR	NYf1fo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DpcmlEPTB;MkGuOVAzKM7:TR?=	Ml\UV2FPT0WU
DoTc2-4510	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn[3TWM2OD1{Mz64OFc2KM7:TR?=	MnTWV2FPT0WU
ABC-1	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJ4Lke5OVch\|ryP	NF60dlRUSU6JRWK=
MHH-NB-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTN\|LkO0OlQh\|ryP	NX;pbm5xW0GQR1XS
SW1463	M3rPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXo[nE3UUN3ME2zN{46QDNizszN	NGTV[HhUSU6JRWK=
SW1417	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTN5LkC5OVIh\|ryP	M1jsc3NCVkeHUh?=
NB12	NEfETFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r6RWlEPTB;M{muOFY2PSEQvF2=	M2\TfHNCVkeHUh?=
NY	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorUTWM2OD12MT6zNlAyKM7:TR?=	M1zzVHNCVkeHUh?=
H1048	MlTQRZBweHSxc3nzJGF{e2G7	NUDpXYc3PTByIH7N	MVS3NkBp		M4XjSY5p[W6lZYOgRWJVNTJ4M,MAl4lv\HWlZXSgZZBweHSxc3nz	NVHDbYw6OjV5M{e1OFI>
H86	NXrDb4oxSXCxcITvd4l{KEG\|c3H5	Mnq5OVAxKG6P	M1WzVlczKGh?		MXnubIFv[2W\|IFHCWE0zPjQkgKPpcoR2[2WmIHHwc5B1d3Orcx?=	NXzWb3lrOjV5M{e1OFI>
H196	NH75XIhCeG:ydH;zbZMhSXO\|YYm=	MnnmOVAxKG6P	NHX4Sm44OiCq		M3rjNI5p[W6lZYOgRWJVNTJ4M,MAl4lv\HWlZXSgZZBweHSxc3nz	NYn5TJBrOjV5M{e1OFI>
H446	MX\BdI9xfG:\|aYOgRZN{[Xl?	NF32d5Q2ODBibl2=	M1LwRlczKGh?		MoPKcohidmOnczDBRnQuOjZ\|4pETbY5lfWOnZDDhdI9xfG:\|aYO=	NF7Nc\|MzPTd\|N{W0Ni=>
TFK-1	NEL0bVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13QOVczKGh?	MnzCSG1UVw>?	MlXqTWM2OD12NzDuUS=>	Ml:3NlUyPTJ{NES=
EGI-1	NGHWXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHrnVnU4OiCq	NFW0b2NFVVOR	NV;PZ3gzUUN3ME21N{BvVQ>?	M4G4blI2OTV{MkS0
OCI/AML3	M{HnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmwMlIh\|ryP	MmjwOFghcA>?		NVKybXRT\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JJNmdHWvZYTpcolj	NGT4R2szPDd\|OUO5Ny=>
U937	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G4elAvOiEQvF2=	M2fa[lQ5KGh?		MYLlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	M{jiVVI1PzN7M{mz
MOLM13	Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKwMlIh\|ryP	MWi0PEBp		MknG[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IIPlcJVu\XSrbnni	MVyyOFc{QTN7Mx?=
MCF7	NX7XT5VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWyNEBvVQ>?	NGPrNIo4OiCq	MnfLSmJU	NYPKV\|dKemWmdXPld{B1cGViUFXMVFEudWWmaXH0[YQhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJk>	MYWyOFY5QDB2Nh?=
TamR	NVjVSZhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7RU5JKSzVyPUG45qCKdk1?	M1TBd\|I1PDV5ME[5
MCF7-X	NEXIZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkC0TWM2OD1{NDDuUS=>	MV6yOFQ2PzB4OR?=
T47D-tamR	NX3ad5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF2yOYZKSzVyPUG5JI5O	MXmyOFQ2PzB4OR?=
293T	NH;wZlJHfW6ldHnvckBCe3OjeR?=	M3niSVIxKG6P	NVrIenV7OyCq		NIjUWIplcXO{dYD0d{BCc3RvbXXkbYF1\WRiVFnGMWlCKHO2YXLpcIl1gSxidILhcpNtd2OjdHnvckwh[W6mIHHjeIl3cXS7	Mn3NNlQ{PjN2NEm=
SW620	M{\4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fsdVAvODBzLUGw{txO	NHfmVlkzPCCq		MmDzbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjczD0bIUh[2:wY3XueJJifGmxbjDybZNmew>?	NVTGfIJ2OjR\|NkO0OFk>
Huh7	MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUC1MVExOCCwTR?=	NYr4XG81OC1{NDDo	NHTJfW9FVVOR	MXzpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MoryNlQzQTd\|MEC=
Hep3B	NYDVfpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPv[Y0xPS1zMECgcm0>	MoXDNE0zPCCq	MoHzSG1UVw>?	NXPQUod[cW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	M4TEOVI1Ojl5M{Cw
Huh7	NFy2NFVHfW6ldHnvckBCe3OjeR?=	NEHTbFQyODBibl2=	NVvtZ5JjOTJiaB?=	M2jkXGROW09?	M3Pyc4lv\HWlZYOgZZV1d3CqYXf5xsA>	NUP2UI53OjR{OUezNFA>
U87-MG	NFfLbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYi3NkBp		Mnr6S2k2OOLCiU5ihKk4QSCwTdMg	MUWyOFI1QTZ2MB?=
L3.6pl	NFi0N5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWK1[GczOSEQvF2=	MlruO\|IhcA>?		NFzrWoxqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCETWOtO\|c4PjB5	MlzxNlQzOzN\|OUm=
TE671	M1jSdGFxd3C2b4Ppd{BCe3OjeR?=	MYexJO69VQ>?	M3qwU\|Q5KGh?		NW\0TWkzcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	M3HzSVI1OTN\|MkG4
RD	NEfqbnRCeG:ydH;zbZMhSXO\|YYm=	M3njTlEh\|ryP	NXvrRVZtPDhiaB?=		MkPtbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	MlrJNlQyOzN{MUi=
RMS13	MlTsRZBweHSxc3nzJGF{e2G7	MlzCNUDPxE1?	MlTIOFghcA>?		Mm\wbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	MVqyOFE{OzJzOB?=
RH30	NFjnbFVCeG:ydH;zbZMhSXO\|YYm=	NE\Id3EyKM7:TR?=	NWm5dFltPDhiaB?=		MULpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDBRnQuPzN5	NG\xSVkzPDF\|M{KxPC=>
Hep-2	M1zjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\aUWhpOC5yMT2xJO69VQ>?	M3LnWFEzNTl4IHi=		MnHvbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	Moj1NlQyODN5NEm=
SCC-9	M3TGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jlSlAvODFvMTFOwG0>	MmKzNVIuQTZiaB?=		NHjqemlqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	NYLUeXAxOjRzMEO3OFk>
Hep-2	MUDGeY5kfGmxbjDBd5NigQ>?	NHz4bo4xNjFxMD61JO69VQ>?	MUSyOEBp		NIraXlhjdG:la4OgcXRQWkNzIHHu[EBuXE:UQ{KgZYN1cX[jdHnvci=>	MVSyOFExOzd2OR?=
SCC-9	NX;6ZnhFTnWwY4Tpc44hSXO\|YYm=	MkfQNE4yNzBwNTFOwG0>	MnjiNlQhcA>?		M3y5NIJtd2OtczDtWG9TSzFiYX7kJI1VV1KFMjDhZ5RqfmG2aX;u	MYGyOFExOzd2OR?=
PANC-1	MUnBdI9xfG:\|aYOgRZN{[Xl?	Moe5OVAxKG6P	MmP2OFghcA>?		NIj6fIl{\W6\|aYTpfoV{KHCjbnPy[YF1cWNiY3HuZ4VzKGOnbHzzJJRwKHKjZHnveIhmemGyeR?=	MmTINlM5QDZ{OUS=
RMG2	MVLBdI9xfG:\|aYOgRZN{[Xl?	MX:xMVExODBibl2=	MorUO\|IhcA>?	NX;1e4tbTkKV	MUjpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	MVyyN\|YyPTZ\|MR?=
HAC2	Mn3ZRZBweHSxc3nzJGF{e2G7	MnKwNU0yODByIH7N	MnjjO\|IhcA>?	MoPRSmJU	Mn7lbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	MojsNlM3OTV4M{G=
HT-29	MlPTRZBweHSxc3nzJGF{e2G7	M4TpRlEh\|ryP	NX7DTHlbPzJiaB?=		MVrheJRmdnWjdHXzJFUuTlVvaX7keYNm\CClZXzsJIRm[XSq	NIXxfHQzOTl2OUGyNS=>
DLD1	NWi3cXRsSXCxcITvd4l{KEG\|c3H5	M4TJNlEh\|ryP	NXztUlRsPzJiaB?=		NW\BZpRk[XS2ZX71ZZRmeyB3LV\VMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	NH3IXnQzOTl2OUGyNS=>
HT-29	MnnpSpVv[3Srb36gRZN{[Xl?	M2jXZVEh\|ryP	MUm3NkBp		MULpcoR2[2W\|IHH1eI9xcGGpeTD0c{Bkd26oZYKgZ5l1d3C{b4TlZ5Rqd25?	Ml\ONlE6PDlzMkG=
DLD1	M3G5T2Z2dmO2aX;uJGF{e2G7	M4fOfFEh\|ryP	NVLBRYdVPzJiaB?=		NVvTd\|V6cW6mdXPld{BifXSxcHjh[5khfG9iY3;u[oVzKGO7dH;wdo91\WO2aX;u	MUmyNVk1QTF{MR?=
Rh41	NHP1RnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTaTWM2OD1\|MD63JI5O	MXGyNVM{PzZ5OR?=
Rh18	M{HwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzWO41RUUN3ME20NU41KG6P	M2O2S\|IyOzN5Nke5
Rh30	NVXFcI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXSe4hKSzVyPUG0JI5O	M2H3[\|IyOzN5Nke5
BT-12	NEDPfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDafXBRUUN3ME2yOE44KG6P	M1jnPFIyOzN5Nke5
CHLA-266	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTFwMTDuUS=>	M{LCN\|IyOzN5Nke5
TC-71	NXTNVoN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvGTWM2OD12Nj61JI5O	M{XXVFIyOzN5Nke5
CHLA-9	M4WxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF3LkOgcm0>	M3fzWVIyOzN5Nke5
CHLA-10	NGLmeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rkTGlEPTB;Mz65JI5O	Ml64NlE{Ozd4N{m=
CHLA-258	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHO3SoRKSzVyPUGwMlQhdk1?	Ml35NlE{Ozd4N{m=
GBM2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4j2UGlEPTB;NECuO{BvVQ>?	NYPqe\|BTOjF\|M{e2O\|k>
NB-1643	NYLDdWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFT0dmFKSzVyPUOzMlghdk1?	NXK3cHJoOjF\|M{e2O\|k>
NB-EBc1	NHXlZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTJ5LkGgcm0>	M2raSFIyOzN5Nke5
CHLA-90	M1TOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\OTWM2OD1\|ND61JI5O	MYmyNVM{PzZ5OR?=
CHLA-136	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTpNGlIUUN3ME2xOlIvPiCwTR?=	M4PFflIyOzN5Nke5
NALM-6	NH:4e5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTN{Lkmgcm0>	NXW4bmRuOjF\|M{e2O\|k>
COG-LL-317	NH3uO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\LeWlEPTB;MT6zJI5O	NX\6UYNVOjF\|M{e2O\|k>
RS4;11	NV3mUWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDJTWM2OD1\|NTDuUS=>	NWfVZnhkOjF\|M{e2O\|k>
MOLT-4	NX7CUJJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3XN\|l1UUN3ME24MlYhdk1?	NUG3bWJ1OjF\|M{e2O\|k>
CCRF-CEM	NFTYVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnmSlYzUUN3ME20MlEhdk1?	MnT1NlE{Ozd4N{m=
Kasumi-1	NGfu[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPle3pKSzVyPUGuOEBvVQ>?	MnzlNlE{Ozd4N{m=
Karpas-299	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnGRoFxUUN3ME2yNU44KG6P	MYOyNVM{PzZ5OR?=
Ramos-RA1	NHftXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3uwTGlEPTB;OD6yJI5O	MoLaNlE{Ozd4N{m=
H838	NIHrbYVHfW6ldHnvckBCe3OjeR?=	MlLzNUDPxE1?	NHvBO3Q1QCCq		NXmwcZUxcW6mdXPld{Bk\WyuIHH1eI9xcGGpeR?=	MkjQNlA{PjRzMUO=
H838	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjrUFIxNTNizszN	MX:3NkBp		M2LEcolv\HWlZYOg[5Jwf3SqIHnubIljcXSrb36gZY5lKGG3dH;wbIFogQ>?	NIHnVIYzODB{OEi1OC=>
A549	NV;RdGJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\TfGIxNTNizszN	NXLJUFRvPzJiaB?=		NITBRphqdmS3Y3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CCjdYTvdIhi\3l?	MYCyNFAzQDh3NB?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	- Collapse Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Formulation: Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v) Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

- Collapse

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 113 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 113 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)